1. Home
  2. NEO vs MESO Comparison

NEO vs MESO Comparison

Compare NEO & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NEO
  • MESO
  • Stock Information
  • Founded
  • NEO 2001
  • MESO 2004
  • Country
  • NEO United States
  • MESO Australia
  • Employees
  • NEO N/A
  • MESO N/A
  • Industry
  • NEO Precision Instruments
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NEO Health Care
  • MESO Health Care
  • Exchange
  • NEO Nasdaq
  • MESO Nasdaq
  • Market Cap
  • NEO 1.1B
  • MESO 1.3B
  • IPO Year
  • NEO 1999
  • MESO N/A
  • Fundamental
  • Price
  • NEO $9.15
  • MESO $19.75
  • Analyst Decision
  • NEO Buy
  • MESO Buy
  • Analyst Count
  • NEO 10
  • MESO 2
  • Target Price
  • NEO $12.56
  • MESO $24.00
  • AVG Volume (30 Days)
  • NEO 3.0M
  • MESO 299.2K
  • Earning Date
  • NEO 10-28-2025
  • MESO 08-28-2025
  • Dividend Yield
  • NEO N/A
  • MESO N/A
  • EPS Growth
  • NEO N/A
  • MESO N/A
  • EPS
  • NEO N/A
  • MESO N/A
  • Revenue
  • NEO $689,189,000.00
  • MESO $17,198,000.00
  • Revenue This Year
  • NEO $10.40
  • MESO $288.50
  • Revenue Next Year
  • NEO $10.11
  • MESO $167.17
  • P/E Ratio
  • NEO N/A
  • MESO N/A
  • Revenue Growth
  • NEO 9.70
  • MESO 191.39
  • 52 Week Low
  • NEO $4.72
  • MESO $7.09
  • 52 Week High
  • NEO $19.12
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • NEO 67.00
  • MESO 69.40
  • Support Level
  • NEO $7.56
  • MESO $17.10
  • Resistance Level
  • NEO $9.24
  • MESO $18.91
  • Average True Range (ATR)
  • NEO 0.36
  • MESO 0.53
  • MACD
  • NEO 0.06
  • MESO 0.27
  • Stochastic Oscillator
  • NEO 92.86
  • MESO 92.54

About NEO NeoGenomics Inc.

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: